Patient Reported Outcomes With LASIK: PROWL-2

This study is currently recruiting participants.
Verified July 2012 by Food and Drug Administration (FDA)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Food and Drug Administration (FDA)
ClinicalTrials.gov Identifier:
NCT01655420
First received: July 30, 2012
Last updated: July 31, 2012
Last verified: July 2012

July 30, 2012
July 31, 2012
July 2012
 
 
 
Complete list of historical versions of study NCT01655420 on ClinicalTrials.gov Archive Site
 
 
 
 
 
Patient Reported Outcomes With LASIK: PROWL-2
Patient-Reported Outcomes With LASIK: PROWL-2

This study evaluates a questionaire designed to measure satisfaction and ophthalmic-related quality of life (QoL) of 300 civilian participants prior to and three months following state-of-the-art laser in situ keratomileusis (LASIK).

The LASIK Quality of Life Collaboration Project (LQOLCP) is a government partnership among the FDA's Center for Devices and Radiological Health (CDRH), the Department of Defense, and the National Eye Institute (NEI). This project examines patient-reported outcomes (PROs) following LASIK surgery. This three-phased project is part of FDA's ongoing effort to better monitor and improve the safety and effectiveness of lasers used in LASIK surgery. PROWL-2 is the third phase of the larger LQOLCP project. The primary objective of PROWL-2 is to explore the psychometric properties of a computer-based questionnaire assessing the patient-reported outcomes of satisfaction and ophthalmic-related quality of life before and over a period of 3 months following LASIK. This questionnaire initially developed and examined in PROWL-1 (a military population) will be examined psychometrically in a civilian population. PROWL-2 is a prospective, multi-center, observational study in which a participant's pre-operative status will serve as the baseline for one-month and three-month post-surgical comparisons. Three hundred (300) participants planning to undergo refractive surgery using LASIK for myopia, hyperopia, or astigmatism will be enrolled in this study from five (5) clinical sites across the United States. Additionally, routine clinical data will be collected pre- and post-operatively (e.g., best corrected visual acuity, manifest refraction, wavefront aberrometry, conreal topography, and other clinical assessments) and questionnaires will be independently administered pre-operatively and at the one-month and three-month post-operative visits.

Observational
Observational Model: Cohort
Time Perspective: Prospective
 
Non-Probability Sample

Individuals age of 21 to 84 years planning to undergo refractive surgery using LASIK for myopia, hyperopia, or astigmatism

Laser in Situ Keratomileusis
Procedure: LASIK
Laser eye surgery
Other Name: Refractive surgery using LASIK for myopia, hyperopia, or astigmatism
LASIK
Individuals aged 21 to 84 years planning to undergo refractive surgery using LASIK for myopia, hyperopia, or astigmatism
Intervention: Procedure: LASIK
 

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
 
 

Inclusion Criteria:

  • Investigators will be instructed to base subject eligibility on the Professional Use Information for their specific laser and keratome system, including but not limited to subjects who:
  • Are aged 21 years or older.
  • Have the ability to give informed consent.
  • Speak and read English fluently.
  • Have not previously had any form of refractive surgery, including prior LASIK or cataract surgery.
  • May benefit from increased spectacle independence.
  • Have been determined to be a good candidate for the LASIK procedure based on the investigator's assessment of medical and ophthalmic health, general cognitive function, and physical and social limitations.
  • Have a treatment target of bilateral emmetropia. Of note, an eye must be treated within 7 days of the fellow eye.
  • Express willingness and potential ability to return for all follow-up examinations through the 3-month follow-up exam under the care of the treating investigator.
  • Have access to a computer with internet service.
Both
21 Years to 84 Years
No
 
United States
 
NCT01655420
20112124
No
Food and Drug Administration (FDA)
Food and Drug Administration (FDA)
National Eye Institute (NEI)
 
Food and Drug Administration (FDA)
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP